ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors to Get Counsel Ahead of Important Deadline in Securities Class Action

0

NEW YORK, April 8, 2022 /PRNewswire/ —

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of AbbVie Inc. (NYSE: ABBV) securities between April 30, 2021 and August 31, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to act as lead plaintiff, you must move the Court not later than June 6, 2022.

SO WHAT: If you purchased AbbVie securities during the Class Period, you may be entitled to compensation without payment of disbursements or fees through a contingency fee arrangement.

WHAT TO DO NEXT: To join the AbbVie class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=5119 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for more information on the class action. A class action lawsuit has already been filed. If you wish to act as lead plaintiff, you must move the Court not later than June 6, 2022. A lead plaintiff is a representative party acting on behalf of other class members to direct litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified attorneys with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company obtained more than $438 million for investors. In 2020, founding partner Laurence Rosen has been named by law360 as a Titan of the Plaintiffs Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants throughout the class action period made false and/or misleading statements and/or failed to disclose that: (1) the safety concerns regarding Xeljanz and Xeljanz XR extended to Rinvoq and other Janus kinase (JAK) inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and delay approval of additional treatment indications for Rinvoq; and (3) therefore, the defendants’ statements regarding AbbVie’s business, operations and prospects lacked a reasonable basis. When the real details entered the market, the lawsuit claims investors suffered damages.

To join the AbbVie class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=5119 or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for more information on the class action.

No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent group member and do nothing at this point. An investor’s ability to participate in any potential future recovery does not depend on their status as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertisement. Previous results do not guarantee a similar result.

Contact information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, Pennsylvania
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

SOURCE Rosen Law Firm, Pennsylvania

Share.

About Author

Comments are closed.